2016
Polygenic risk of Alzheimer disease is associated with early- and late-life processes
Mormino EC, Sperling RA, Holmes AJ, Buckner RL, De Jager PL, Smoller JW, Sabuncu MR, Weiner M, Aisen P, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Saykin A, Morris J, Liu E, Green R, Montine T, Petersen R, Aisen P, Gamst A, Thomas R, Donohue M, Walter S, Gessert D, Sather T, Beckett L, Harvey D, Gamst A, Donohue M, Kornak J, Jack C, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Jagust W, Bandy D, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Morris J, Cairns N, Taylor-Reinwald L, Trojanowki J, Shaw L, Lee V, Korecka M, Toga A, Crawford K, Neu S, Saykin A, Foroud T, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder P, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider L, Pawluczyk S, Spann B, Brewer J, Vanderswag H, Heidebrink J, Lord J, Petersen R, Johnson K, Doody R, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig L, Bell K, Morris J, Ances B, Carroll M, Leon S, Mintun M, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah R, Duara R, Varon D, Roberts P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon M, Glodzik L, De Santi S, Doraiswamy P, Petrella J, Coleman R, Arnold S, Karlawish J, Wolk D, Smith C, Jicha G, Hardy P, Lopez O, Oakley M, Simpson D, Porsteinsson A, Goldstein B, Martin K, Makino K, Ismail M, Brand C, Mulnard R, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey A, Lah J, Cellar J, Burns J, Anderson H, Swerdlow R, Apostolova L, Lu P, Bartzokis G, Silverman D, Graff-Radford N, Parfitt F, Johnson H, Farlow M, Hake A, Matthews B, Herring S, van Dyck C, Carson R, MacAvoy M, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Robin Hsiung G, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam M, Lipowski K, Wu C, Johnson N, Sadowsky C, Martinez W, Villena T, Turner R, Johnson K, Reynolds B, Sperling R, Johnson K, Marshall G, Frey M, Yesavage J, Taylor J, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson A, Norbash A, Johnson P, Obisesan T, Wolday S, Bwayo S, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, Olichney J, DeCarli C, Kittur S, Borrie M, Lee T, Bartha D, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre D, Kataki M, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Saykin A, Santulli R, Schwartz E, Sink K, Williamson J, Garg P, Watkins F, Ott B, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen H, Miller B, Mintzer J, Longmire C, Spicer K, Finger E, Rachinsky I, Rogers J, Kertesz A, Drost D, Pomara N, Hernando R, Sarrael A, Schultz S, Boles Ponto L, Shim H, Smith K, Relkin N, Chaing G, Raudin L, Smith A, Fargher K, Raj B. Polygenic risk of Alzheimer disease is associated with early- and late-life processes. Neurology 2016, 87: 481-488. PMID: 27385740, PMCID: PMC4970660, DOI: 10.1212/wnl.0000000000002922.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlzheimer DiseaseAmyloid beta-PeptidesAniline CompoundsAtrophyBiomarkersCognition DisordersCohort StudiesEarly DiagnosisEthylene GlycolsFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHippocampusHumansMaleMemory DisordersMultifactorial InheritancePolymorphism, Single NucleotidePositron-Emission TomographyYoung AdultConceptsHigher polygenic risk scorePolygenic risk scoresHippocampus volumeRisk scoreLarge observational cohort studyCommon genetic risk lociSmaller hippocampus volumesΒ-amyloid burdenObservational cohort studyGenetic riskElevated polygenic risk scoresAlzheimer's disease markersCSF β-amyloidLongitudinal cognitive declineHealthy young participantsCohort studyClinical progressionClinical symptomsAD dementiaAD markersSmaller hippocampiFlorbetapir PETAggregate genetic riskΒ-amyloidGenome-wide association studies
2015
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Minthon L, Blennow K, Olsson M, Hansson O, Hansson O, Minthon L, Toresson H, Nägga K, Palmqvist S, Stomrud E, Johansson P, Nilsson C, Nilsson M, Mattsson N, Lindqvist D, Vestberg S, Janelidze S, Zetterberg H, Blennow K, Andreasson U, van Westen D, Lätt J, Mannfolk P, Nilsson M, Strandberg O, Sundgren P, Ståhlberg F, Lindberg O, Westman E, Wahlund L, Wollmer P, Smith R, Olsson T, Weiner M, Aisen P, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Gamst A, Saykin A, Morris J, Potter W, Green R, Montine T, Petersen R, Aisen P, Gamst A, Thomas R, Donohue M, Walter S, Jack C, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Jagust W, Bandy D, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Morris J, Cairns N, Taylor-Reinwald L, Trojanowki J, Shaw L, Lee V, Korecka M, Toga A, Crawford K, Neu S, Beckett L, Harvey D, Gamst A, Kornak J, Saykin A, Foroud T, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder P, Molchan S, Kaye J, Dolen S, Quinn J, Schneider L, Pawluczyk S, Spann B, Brewer J, Vanderswag H, Heidebrink J, Lord J, Petersen R, Johnson K, Doody R, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig L, Bell K, Morris J, Mintun M, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Tang C, Marzloff G, deToledo-Morrell L, Shah R, Duara R, Varon D, Roberts CAN P, Albert M, Kozauer N, Zerrate M, Rusinek H, de Leon M, De Santi S, Doraiswamy P, Petrella J, Aiello M, Arnold S, Karlawish J, Wolk D, Smith C, Given C, Hardy P, Lopez O, Oakley M, Simpson D, Ismail M, Brand C, Richard J, Mulnard R, Thai G, Mc-Adams-Ortiz C, Diaz-Arrastia R, Martin-Cook K, DeVous M, Levey A, Lah J, Cellar J, Burns J, Anderson H, Laubinger M, Apostolova L, Silverman D, Lu P, Graff-Radford N, Parfitt F, Johnson H, Farlow M, Herring S, Hake A, van Dyck C, MacAvoy M, Benincasa A, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Robin Hsiung G, Feldman H, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Wu C, Johnson N, Mesulam M, Sadowsky C, Martinez W, Villena T, Turner R, Johnson K, Reynolds B, Sperling R, Rentz D, Johnson K, Rosen A, Tinklenberg J, Ashford W, Sabbagh M, Connor D, Jacobson S, Killiany R, Norbash A, Nair A, Obisesan T, Jayam-Trouth A, Wang P, Lerner A, Hudson L, Ogrocki P, DeCarli C, Fletcher E, Carmichael O, Kittur S, Borrie M, Lee T, Bartha R, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Hendin B, Scharre D, Kataki M, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Saykin A, Santulli R, Englert J, Williamson J, Sink K, Watkins F, Ott B, Stopa E, Tremont G, Salloway S, Malloy P, Correia S, Rosen H, Mintzer J, Longmire C, Spicer K. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 2015, 85: 1240-1249. PMID: 26354982, PMCID: PMC4607601, DOI: 10.1212/wnl.0000000000001991.Peer-Reviewed Original ResearchConceptsEarly Alzheimer's diseaseCSF biomarkersEarly-stage Alzheimer's diseaseAlzheimer's diseasePET measuresAmyloid PETT-tauMCI-ADPET biomarkersAβ42/P-tauDiagnostic accuracyClass III evidenceΒ-amyloid depositionMild cognitive impairmentHigh diagnostic accuracyAβ depositionP-tauTotal tauAD dementiaCSF Aβ42Patient preferencesCSF measuresEuroimmun ELISAAlzheimer's Disease Neuroimaging Initiative studyBioFINDER study